Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 20/20 | 1.00 |
| ▸ | MMP9 | P14780 | 20/20 | 1.00 |
| ▸ | MMP13 | P45452 | 4/20 | 0.80 |
| ▸ | MMP3 | P08254 | 3/20 | 0.80 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MMP1 | P03956 | 1/20 | 0.42 |
| ▸ | MMP8 | P22894 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8203763 | 1.00 | MMP2 (1.00) | MMP2MMP9MMP13MMP3CA1 | |
| SCHEMBL8209543 | 0.90 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL3109502 | 0.90 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL3098154 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP13MMP3 | |
| SCHEMBL13074271 | 0.89 | MMP2 (1.00) | MMP2MMP9MMP13MMP3 | |
| SCHEMBL3111538 | 0.88 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL8204841 | 0.88 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP1 | |
| SCHEMBL13036925 | 0.86 | MMP2 (0.85) | MMP2MMP9MMP13MMP3 | |
| SCHEMBL8203481 | 0.86 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP8 | |
| SCHEMBL8197033 | 0.86 | MMP2 (1.00) | MMP2MMP9MMP13MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-11-04 | — | — | US | disclosed |
| US-7803793-B2 | Heterocyclic derived metalloprotease inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-28 | — | — | US | disclosed |
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103129-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885MMP13 29/4885 |
| US-20100279986-A1 | HETEROCYCLIC DERIVED METALLOPROTEASE INHIBITORS | ADAM17, MMP25, ADAM33 | MMP2 16/4885MMP9 8/4885MMP13 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.